← Back to Search

Photoacoustic Imaging for Lymph Node Cancer

Q: Are there available openings for this experimental procedure?

<p><a href="https://www.withpower.com/clinical-trials/all">All</a> evidence points to this medical trial being open for enrollment. Initially posted on January 26th 2021, its most recent revision was made October 28th 2022.</p>

Q: What is the sample size of this experiment?

<p>Indeed, the information available on clinicaltrials.gov attests to this study's current recruitment process. Its first listing was posted in January 2021 and has been continually updated since then; currently 10 people are needed at one trial location.</p>

Phase < 1

Waitlist Available

Led By Priya R Bhosale

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Scheduled to undergo ultrasound-guided fine needle aspiration cytology or biopsy

Pathologically proven primary malignancy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 months

Awards & highlights

Study Summary

This trial uses ultrasound & light to detect cancer in groin lymph nodes, which may help prevent unnecessary surgery.

Who is the study for?

This trial is for cancer patients with suspicious groin lymph nodes identified by standard imaging and scheduled for needle aspiration or biopsy. It's not suitable for melanoma patients or those with deep (3-5 cm) or small (<1 cm) lymph nodes.Check my eligibility

What is being tested?

The study tests ultrasound-guided photoacoustic imaging to distinguish between healthy and cancerous groin lymph nodes, aiming to improve tumor staging and reduce unnecessary surgeries.See study design

What are the potential side effects?

As a non-invasive imaging technique, ultrasound-guided photoacoustic imaging has minimal side effects, primarily related to the discomfort from the ultrasound procedure itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for a needle biopsy guided by ultrasound.

Select...

My cancer diagnosis was confirmed through a biopsy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Difference between background oxygen saturation (%sO2) and nodal %sO2

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)Experimental Treatment5 Interventions

Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fine-Needle Aspiration

2018

Completed Early Phase 1

~40

Ultrasound

2013

Completed Phase 1

~1950

Lymph Node Biopsy

2014

Completed Phase 2

~50

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,967 Previous Clinical Trials

1,804,779 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,644 Total Patients Enrolled

Priya R BhosalePrincipal InvestigatorM.D. Anderson Cancer Center

3 Previous Clinical Trials

20,071 Total Patients Enrolled

Media Library

Multispectral optoacoustic tomography (MSOT) acuity instrument Clinical Trial Eligibility Overview. Trial Name: NCT04185337 — Phase < 1

Cancer Research Study Groups: Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)

Cancer Clinical Trial 2023: Multispectral optoacoustic tomography (MSOT) acuity instrument Highlights & Side Effects. Trial Name: NCT04185337 — Phase < 1

Multispectral optoacoustic tomography (MSOT) acuity instrument 2023 Treatment Timeline for Medical Study. Trial Name: NCT04185337 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there available openings for this experimental procedure?

"All evidence points to this medical trial being open for enrollment. Initially posted on January 26th 2021, its most recent revision was made October 28th 2022."

Answered by AI

What is the sample size of this experiment?

"Indeed, the information available on clinicaltrials.gov attests to this study's current recruitment process. Its first listing was posted in January 2021 and has been continually updated since then; currently 10 people are needed at one trial location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes

2021. "Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04185337.

All > Vestibular Schwannoma